Boston Scientific (NYSE: BSX) Beats Q2 2026 EPS Estimates, Raises Full-Year Adjusted EPS Guidance

Q2 2026 Results

Boston Scientific (NYSE: BSX) reported second-quarter 2026 net sales of $5.442 billion, up 7.5% year over year, with adjusted EPS of $0.86 beating the $0.84 analyst consensus by 3.0%. GAAP net income attributable to common stockholders rose 13.8% year over year to $907 million, or $0.61 per share, compared to $797 million, or $0.53 per share, in the prior-year period.

• Revenue: $5.442B for Q2 2026, up 7.5% on a reported basis and 7.0% on an operational and organic basis versus Q2 2025
• Adjusted EPS: $0.86, above the guidance range of $0.82 to $0.84 and ahead of the $0.84 consensus estimate
• GAAP EPS: $0.61, up 15.1% from $0.53 in Q2 2025
• Cardiovascular segment: Net sales of $3.624B, up 8.3% reported and 7.8% on an organic basis year over year
• MedSurg segment: Net sales of $1.818B, up 5.9% reported and 5.4% on an organic basis year over year
• Latin America and Canada region: Net sales grew 22.4% on a reported basis and 16.2% on an operational basis

What Drove the Results

Adjusted EPS of $0.86 beat the $0.84 consensus by $0.02, while reported revenue of $5.442B came in at the top of the company's own guidance range of 5.5% to 7.5% growth. The Cardiovascular segment, the larger of the two reporting segments at $3.624B, outpaced MedSurg with 8.3% reported growth. Within MedSurg, Neuromodulation was the standout sub-segment, growing 12.7% on a reported basis to $341 million.

Geographically, Asia-Pacific delivered 11.2% reported growth to $878 million, and the Latin America and Canada region posted 22.4% reported growth to $206 million, partially offset by a 6.2% foreign currency headwind in that region. The U.S. segment, the largest geography at $3.426B, grew 6.2% year over year.

During the quarter, Boston Scientific also completed a $2 billion accelerated share repurchase program, retiring approximately 40 million shares. Separately, the company invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire MiRus's transcatheter aortic valve replacement business.

Guidance and Outlook

For the third quarter of 2026, Boston Scientific guided for net sales growth of 3% to 5% on both a reported and organic basis, and adjusted EPS of $0.80 to $0.82. For the full year 2026, the company now expects net sales growth of approximately 5.5% to 6.5% on a reported basis and 5% to 6% on an organic basis, with full-year adjusted EPS in the range of $3.28 to $3.32. Third-quarter revenue guidance of approximately $5.27 billion came in 2.2% below analyst consensus estimates, according to market reports.

Wall Street View

Analyst sentiment on BSX heading into the print was broadly constructive, with the majority of covering firms at Buy or equivalent ratings. No specific new price target actions were available in the source data for this reporting date.

Investor Takeaway

Boston Scientific's Q2 2026 results show consistent top- and bottom-line execution, with adjusted EPS growth of 14.7% year over year to $0.86 and revenue growth of 7.5%. The raised full-year adjusted EPS guidance to $3.28-$3.32 reflects management confidence in the remainder of 2026, even as third-quarter revenue guidance arrived modestly below Street expectations. The $1.5 billion MiRus investment and the completed $2 billion share repurchase represent two concurrent capital allocation commitments that investors will watch for balance sheet and strategic impact in coming quarters.